Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Methods for generating a Zikv immune response utilizing a recombinant modified vaccina Ankara vector encoding the NS1 protein

Methods for generating a Zikv immune response utilizing a recombinant modified vaccina Ankara vector encoding the NS1 protein

US Patent 11638750 · Granted May 2, 2023

Estimated economic value: $928,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Replication-deficient modified vaccinia ankara (MVA) expressing marburg virus gl2025
Compositions and methods for generating an immune response to treat or prevent m2025
Compositions and methods for generating an immune response to treat or prevent m2025
Compositions and methods for generating an immune response to treat or prevent m2025
Vaccinia viral vectors encoding chimeric virus like particles2025
Vaccinia viral vectors encoding chimeric virus like particles2025
Vaccinia viral vectors encoding chimeric virus like particles2025
Replication-deficient modified vaccinia Ankara (MVA) expressing Marburg virus gl2024
Compositions and methods for generating an immune response to treat or prevent m2024
Compositions and methods for generating an immune response to treat or prevent m2024
Compositions and methods for generating an immune response to treat or prevent m2024
Compositions and methods for generating an immune response to hepatitis B virus2023